The coronavirus disease 2019 (COVID-19) is induced by the SARS-CoV-2 virus, which caused the global pandemic, infecting approximately 608.328.548 confirmed cases and bringing about 6.501.469 deaths worldwide, as WHO stated in September 2022. The disease is more deadly due to the lack of specific drug molecules or a treatment plan. Therefore, the development of potent pharmacological compounds is urgently required to combat COVID-19. Due to their biological actions, snake venoms constitute a source of potentially beneficial medicinal compounds. Vipera ammodytes ammodytes (VA) is a viper species whose venom has been shown to have anti-proliferative, antimetastatic, anti-cancer, and anti-microbial activities. This in silico study was conducted to evaluate the efficacy of selected VA venom proteins (Adamalysin II, Ammodytoxin A, Ammodytin L, L-amino acid oxidase) against molecular targets; Main protease (3CLpro) and Angiotensin-Converting Enzyme 2 (ACE2) by molecular docking study. Molecular docking investigations were performed by using AutoDock Vina software. All compounds displayed negative binding energy values to 3CLpro and ACE2, suggesting that their interactions with the active sites were favourable. L-amino acid oxidase had the highest binding affinity with both 3CLpro and ACE2. This study revealed for the first time that VA venom proteins are functional inhibitors of 3CLpro and ACE2 activities, and the components of VA venom can be considered potential SARS-CoV-2 inhibitors. However, more studies are needed to validate these compounds in vitro and in vivo.
Vipera ammodytes ammodytes SARS-CoV-2 molecular docking venom ACE2 3CLpro
Birincil Dil | İngilizce |
---|---|
Konular | Yapısal Biyoloji |
Bölüm | Biyoloji / Biology |
Yazarlar | |
Erken Görünüm Tarihi | 27 Mayıs 2023 |
Yayımlanma Tarihi | 1 Haziran 2023 |
Gönderilme Tarihi | 24 Eylül 2022 |
Kabul Tarihi | 4 Şubat 2023 |
Yayımlandığı Sayı | Yıl 2023 Cilt: 13 Sayı: 2 |